Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
New Mexico Cancer Research Alliance
This is a single-arm, non-randomized Phase II trial of docetaxel given every 3 weeks with metformin twice daily and Prednisone twice daily. The study duration of this trial is open ended. The patient would take the metformin only for as long as they are treated with docetaxel.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
All patients, 18 of age or older, with hormone refractory prostate cancer are eligible.
Patients must have a life expectancy of at least 12 weeks.
Patients must have a Zubrod performance status of 0-2.
Patients must sign an informed consent.
Patients should have adequate bone marrow function defined by an absolute peripheral granulocyte count of \> 1,500 or cells/mm3 and platelet count \>100,000/mm3 and absence of a regular red blood cell transfusion requirement.
Patients should have adequate hepatic function with a total bilirubin \< 2 mg/dl and SGOT or SGPT \< two times the upper limit of normal, and adequate renal function as defined by a serum creatinine \< 1.5 x upper limit of normal.
Patients must have pathologically confirmed prostate cancer with PSA increasing despite androgen deprivation therapy.
Diabetic patients on therapy with Metformin are eligible provided that their Metformin dose is at least 850mg twice daily.
You may not be if
Patients with symptomatic brain metastases are excluded from this study.
Patients may receive no other concurrent chemotherapy or radiation therapy during this trial.
Clareo Health | Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer
